SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending as investors digest recent earnings and a newly authorized share buyback, with community sentiment split between those seeing a buying opportunity at lower prices and others expressing concerns about competition and overall market conditions. Some analysts are maintaining positive outlooks, while community members debate the impact of political ad spending and potential for a short squeeze. Technical analysis suggests the stock is oversold, potentially setting up for a reversal.

CarMax, Inc. is a holding company, which engages in the retail of used vehicles and wholesale of vehicle auction operators. It operates through the CarMax Sales Operations and CarMax Auto Finance (CAF) segments. The CarMax Sales Operations segment consists of all aspects of its auto merchandising and service operations. The CAF segment pertains to its finance operation, which offers vehicle financing services to customers buying retail vehicles. The company was founded by Richard L. Sharp and William Austin Ligon in 1993 and is headquartered in Richmond, VA.

Carmax Inc

CarMax ($KMX) is trending as investors assess the impact of a CEO change and weak preliminary results, while the community debates whether it's a buying opportunity or a sign of deeper issues. Some believe the stock is undervalued, citing BlackRock's ownership and potential for a price jump with a new CEO, while others point to downgrades and comparisons to Carvana ($CVNA) as reasons for concern amid a challenging used car market.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending as community members rally around the project's real-world applications and growing brand presence, emphasizing their active involvement and long-term vision. The community highlights KENDU's expanding ecosystem, including energy drinks, merchandise, and a passionate street team, reinforcing their commitment to building a recognizable global brand. Enthusiasts express strong conviction in KENDU's potential, promoting its unique position as a community-driven brand coin.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending following news of a multi-year partnership with DoorDash to expand autonomous robot delivery services, with community members anticipating a rise to previous highs. Some are speculating on potential acquisitions and increased revenue in 2026 from expanded robot deployments, while others are closely watching short interest and technical indicators for potential squeeze opportunities. Overall, the community is excited about the potential for autonomous delivery to become mainstream.

Royal Caribbean Group is a cruise company, which engages in the ownership and operation of the following global cruise brands: Royal Caribbean International, Celebrity Cruises, and Silversea Cruises. The firm also holds interest in TUI Cruises GmbH, which operates the German brands TUI Cruises and Hapag-Lloyd Cruises. The company was founded by Arne Wilhelmsen in 1968 and is headquartered in Miami, FL.

Royal Caribbean Group

RCL is trending amid mixed sentiment, with some investors expressing concern over the stock's recent performance and potential overvaluation.  Despite positive comments regarding the cruise industry's recovery, some community members are anticipating a pullback.  Overall, the stock's trajectory and earnings potential are key points of discussion among investors.

Asana, Inc. engages in the business of developing a work management platform that helps organizations orchestrate work from daily tasks to cross-functional strategic initiatives. The company was founded by Dustin Moskovitz and Justin Michael Rosenstein on December 16, 2008 and is headquartered in San Francisco, CA.

Asana Inc - Ordinary Shares - Class A

Asana Inc

Asana is trending amid discussions about its latest earnings report and guidance, with some analysts downgrading the stock despite a revenue beat. The community is focused on insider trading activity, particularly CEO Dustin Moskovitz's past and potential future share purchases, and speculating about a possible buyout. Sentiment is mixed, with some investors expressing frustration and others anticipating a potential squeeze.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster ($OUST) is trending amid analyst upgrades and community optimism, with Cantor Fitzgerald recently adjusting its rating to Overweight.  Investors are actively discussing partnerships with Serve Robotics and May Mobility, as well as potential applications of Ouster's LiDAR technology in self-driving cars and defense.  Community members are also speculating on upcoming earnings and the potential for Ouster to solidify its position in the autonomous vehicle market.

Digital Realty Trust, Inc. operates as a real estate investment trust, which engages in the provision of data center, colocation and interconnection solutions. It serves the following industries: artificial intelligence (AI), networks, cloud, digital media, mobile, financial services, healthcare, and gaming. The company was founded on March 9, 2004, and is headquartered in Dallas, TX.

Digital Realty Trust Inc

Digital Realty is trending as investors discuss the REIT's position to capitalize on AI-driven demand for data centers, with some highlighting the potential for partnerships like the one with NVIDIA to set future standards. Community members are debating valuation metrics like P/E ratio and dividend payout, while analysts are adjusting price targets based on recent earnings and guidance. Discussions also include infrastructure buildout and strategic moves to address enterprise AI challenges.

Nova Minerals Ltd. engages in the exploration and development of mineral properties. Its projects include Estelle Gold, RPM, Korbel, Train, Stoney and Studies projects. The company was founded in January 1987 and is headquartered in Melbourne, Australia.

Nova Minerals Limited - ADR

Nova Minerals is trending as the market anticipates potential benefits from upcoming high-level critical minerals discussions between the U.S. and Australia, especially given the recent Department of Defense grant awarded to the company. Community members are focused on the company's gold and antimony prospects, with some speculating about a possible government stake and significant upside potential.

SolarEdge Technologies, Inc. engages in the development of energy technology, which provides inverter solutions. The firm operates through the following segments: Solar and All Other. The Solar segment includes the design, development, manufacturing, and sales of an inverter solution designed to maximize power generation. The All Other segment includes the design, development, manufacturing and sales of UPS products, energy storage products, e-Mobility products, and automated machines. Its products and services include photovoltaic inverters, power optimizers, photovoltaic monitoring, software tools, and electric vehicle chargers. The company was founded by Guy Sella, Lior Handelsman, Yoav Galin, Meir Adest, and Amir Fishelov on August 7, 2006 and is headquartered in Herzliya, Israel.

Solaredge Technologies Inc

Solaredge Technologies is trending as the stock approaches its 52-week high, with analysts adjusting price targets amid discussions of potential resistance levels. Bullish sentiment is fueled by the company's strategic positioning in the energy sector, while some traders are closely watching short interest and potential pullbacks. Community members are actively debating the stock's valuation and future prospects, considering both bullish and bearish scenarios.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure

KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.

KALA BIO (KALA) announced on Monday that its KPI-012 failed in a mid-stage clinical trial evaluating it as a treatment for persistent corneal epithelial defect.A persistent corneal epithelial defect (PCED) is a corneal injury that fails to heal within the typical timeframe of two weeks, persisting for weeks or even months despite standard treatment. Kala’s study to evaluate the safety and efficacy of two doses of KPI-012 ophthalmic solution did not meet the primary goal of complete healing of PCED at week 8, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.kalarx.com/news-releases/news-release-details/kala-bio-announces-topline-results-chase-phase-2b-clinical-trial">said</a>. It also noted that the secondary goals in the study did not achieve statistical significance, and there was no meaningful difference between the KPI-012 treatment arm and the placebo arm in the trial.The company subsequently decided to cease clinical development of KPI-012 and stated that it is evaluating its strategic options. The firm noted that it intends to preserve cash, including by laying off some of its workforce and implementing other cost-saving measures.Kim Brazzell, Chief Medical Officer of Kala Bio, said that the company is “disappointed” to see the new study results.“KPI-012 continued to be well-tolerated and demonstrated a favorable safety profile but did not demonstrate the efficacy results that would warrant advancing the program for treatment of front-of-the-eye diseases,” he added.Shares of the company slipped 89% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KALA">KALA stock</a> rose to ‘extremely bullish’ from ‘neutral’ territory over the past 24 hours, while message volume rose to ‘extremely high’ from ‘high’ levels.Following the company’s announcement, LifeSci Capital downgraded Kala Pharmaceuticals to ‘Market Perform’ from ‘Outperform’ and removed the firm's price target on the stock.Mizuho analyst Graig Suvannavejh, meanwhile, expressed disappointment that the company did not share any data details or host a call to discuss the study results, as per TheFly. &nbsp;KALA stock is down by 69% this year and by about 62% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dogwood-therapeutics-stock-soars-pre-market-on-securing-license-for-cancer-related-pain-management-drug/chDubC3R3J2">Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Kala Bio Stock Just Plunged 89% Today – Here’s What Happened

The firm stated that its KPI-012 failed in a mid-stage clinical trial and announced that it intends to preserve cash, including by laying off some of its workforce and deploying other cost-saving measures. 

Equity

The firm stated that its KPI-012 failed in a mid-stage clinical trial and announced that it intends to preserve cash, including by laying off some of its workforce and deploying other cost-saving measures. 


Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade

The mean of analysts' price targets for KALA BIO (KALA) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks.com featured highlights include KALA, Graham, Arq and Hawkins

KALA, GHM, ARQ, and HWKN are drawing investor attention after fresh analyst coverage highlights improving outlooks.

Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility

New analyst coverage lifts investor interest in KALA, GHM, ARQ, and HWKN as markets grapple with rising volatility.

Shares of Kala Bio Inc. tumbled over 35% on Wednesday, on track for their worst single-day decline ever, after the company announced the resignation of CEO Mark Iwicki.President Todd Bazemore has been named interim CEO, while Iwicki will remain as chair of the board.&nbsp;Iwicki, who has led Kala for nearly a decade, oversaw multiple phases of drug development.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/KALA_sentiment_and_message_volume_on_Feb_12_cdc55fd016.png" alt="KALA sentiment and message volume on Feb 12.png" width="1318" height="324"><figcaption>KALA sentiment and message volume on Feb 12 as of 2 pm ET | source: Stocktwits</figcaption></figure>Despite the steep selloff, retail traders on Stocktwits believe the market reaction is excessive, as evidenced by the 'extremely bullish' sentiment score.&nbsp;One user argued that Iwicki's departure "is the best thing possible for this company" and could signal a potential sale of the company after Kala's upcoming pipeline update.<stembedurl>https://stocktwits.com/Stmkr/message/603965500</stembedurl><stembedurl>https://stocktwits.com/Sammysums/message/603977842</stembedurl>Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects, a condition that can lead to vision loss.&nbsp;The company is also exploring KPI-012 for Limbal Stem Cell Deficiency and other rare corneal diseases, while its MSC-S platform is in preclinical studies for retinal degenerative conditions like Retinitis Pigmentosa and Stargardt Disease.At the end of 2024, Kala raised approximately $10.8 million through a private placement of common shares and Series I convertible preferred stock with institutional investors.The company is expected to report fourth-quarter earnings in March. Wall Street projects an adjusted loss per share of $2.28, down from $3.62 a year ago, on no revenue.Kala shares are down just 2.2% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction

Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects.

KALA Stock Earnings: Kala Pharmaceuticals Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
KALA stock results show that Kala Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.
The post...

Kala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44

Kala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44...

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash...

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Kala Bio Inc.

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

KALA
Kala Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KALA News

KALAKala Pharmaceuticals Inc